Recruiting studies: Anti Pd 1 Antibody

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910 A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520 A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06642792 Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT03161223 A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029 Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 · 317 location(s) · AstraZeneca · NCT07044336 A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recu
Phase 2/Phase 3 · 295 location(s) · Bristol-Myers Squibb · NCT06926868 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06305962 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626 FS222 First in Human Study in Patients With Advanced Malignancies
Phase 1 · 21 location(s) · invoX Pharma Limited · NCT04740424 A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With An
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT06827236 A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Phase 1 · 4 location(s) · SparX Biotech(Jiangsu) Co., Ltd. · NCT06259552 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.